undamentalytics Newsletter
Sign in

Repligen Corp balance sheet

At the end of fiscal 2025, Repligen Corp had total assets of $2.95bn, total liabilities of $844m and shareholders' equity of $2.11bn. It held $566m in cash against $542m of debt: net cash of $23.8m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Mar 20102011Mar 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents——29403554122174194528717604523751757566727
Receivables—1458111528334371117116124134159151
Inventory—2111212182539425595184238202143170182
Total current assets—566686811031842432766429029329981,1111,0661,1371,242
Goodwill—1111414603273274686188608569871,0311,1141,100
Total assets—72971191281462897447751,4001,9032,3582,5322,8312,8302,9502,926
Accounts payable—1224757101117362820323028
Deferred revenue (current)——1000011515151917131516
Total current liabilities—511111119212513048319375404165127136126
Long-term debt——————95990233244———526542556
Total debt0000009599103288288293285580526542556
Total liabilities—5—————152159340374608621866857844835
Shareholders' equity666784841121231695926161,0601,5291,7501,9111,9651,9732,1062,092
Net debt (negative = net cash)——−29−40−35−54−27−75−90−241−430−310−239−172−232−24−171
Shares outstanding—31m31m32m33m33m34m44m44m52m55m55m56m56m56m56m57m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: NEO vs RGENRGEN vs TXGAZTA vs RGENRGEN vs TECH

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Repligen Corp's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Repligen Corp.